CEL-SCI Corporation's latest marketcap:
As of 07/29/2025, CEL-SCI Corporation's market capitalization has reached $11.91 M. According to our data, CEL-SCI Corporation is the 39746th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 11.91 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -27,270,957 |
| Shares Out | 5.14 M |
| EPS (ttm) | -12.33 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
CEL-SCI Corporation's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/29/2025 | $11.91 M | 1.22% | 39746 |
| 12/31/2024 | $24.6 M | -81.9% | n/a |
| 12/29/2023 | $135.9 M | 32.46% | n/a |
| 12/30/2022 | $102.6 M | -66.58% | n/a |
| 12/31/2021 | $307 M | -33.78% | n/a |
| 12/31/2020 | $463.6 M | 43.22% | n/a |
| 12/31/2019 | $323.7 M | 297.18% | n/a |
| 12/31/2018 | $81.5 M | 226% | n/a |
| 12/29/2017 | $25 M | 96.85% | n/a |
| 12/30/2016 | $12.7 M | -73.6% | n/a |
Company Profile
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Frequently Asked Questions
-
What is CEL-SCI Corporation's (CVM) current market cap?As of 07/29/2025, CEL-SCI Corporation (including the parent company, if applicable) has an estimated market capitalization of $11.91 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does CEL-SCI Corporation (CVM) rank globally by market cap?CEL-SCI Corporation global market capitalization ranking is approximately 39746 as of 07/29/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.